Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD4831 Alone and with Itraconazole
NCT05236543Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma drug concentration, Area under the plasma concentration curve from zero to last quantifiable concentration and 7 more. Started Feb 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05236543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236543.